<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83890">
  <stage>Registered</stage>
  <submitdate>5/05/2009</submitdate>
  <approvaldate>25/05/2009</approvaldate>
  <actrnumber>ACTRN12609000345280</actrnumber>
  <trial_identification>
    <studytitle>Does the peri-articular injection of corticosteroid during knee replacement surgery result in reduced pain and improved knee function ?</studytitle>
    <scientifictitle>The role of intra-operative peri-articular steroid injection in reducing post-operative pain and improving knee function after total knee arthroplasty: a prospective randomised controlled trial.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>arthritis of the knee</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Prospective randomised trial comparing pain/functional outcomes between the intra-operative peri-articular injection of either 0, 20 mg or 40 mg of triamcinolone acetonide</interventions>
    <comparator>The treatment groups will be given either 20 mg or 40 mg triamcinolone acetate as a single dose intra-operatively (added to a local anaesthetic solution). The control group will not have steroid added to their local aesthetic solution (syringe is covered and volume effect is neglible) so I have still classified the control group as placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>knee injury and osteoarthritis outcome score (KOOS) assessing knee pain, function and quality of life</outcome>
      <timepoint>12 weeks after total knee replacement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>knee range of motion as measured by goniometer by the treating surgeon</outcome>
      <timepoint>12 weeks after total knee replacement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>visual analogue pain scale (VAS)</outcome>
      <timepoint>12 weeks after total knee replacement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>knee society score (KSS) measuring knee pain, range of motion, stability and function</outcome>
      <timepoint>12 weeks after total knee replacement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>average daily standardised anagelsic requirements (oxycontin, endone, digesic) as measured by supplied diary (self reporting)</outcome>
      <timepoint>12 weeks after total knee replacement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients undergoing total knee arthroplasty</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>diabetes mellitus requiring insulin replacement
corticosteroid allergy
immunocompromise
chronic regional pain syndromes
workers compensation cases</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subject enrolled by surgeon after excluding contra-indications and informed consent. Allocation to treatment group is performed via randomisation table by our anaesthesist (who is not involved in patient review and data collection). The syringe is covered by an opaque dressing to conceal any cloudiness that may result by the addition of corticosteroid.</concealment>
    <sequence>A randomisation (computer generated)  table was created and the patients allocated to a group in numerical order down the table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Sam Chia</primarysponsorname>
    <primarysponsoraddress>PO Box 634 
Waverley
NSW Australia 2024</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Sam Chia</fundingname>
      <fundingaddress>PO Box 634 
Waverley
NSW, Australia 2024</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Sam Macdessi</sponsorname>
      <sponsoraddress>Suite 211
Edgecliff Centre
203-233 New South Head Road
Edgecliff
NSW Australia 2027</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Darren Chen</othercollaboratorname>
      <othercollaboratoraddress>Suite 211
Edgecliff Centre
203-233 New South Head Road
Edgecliff
NSW Australia 2027</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Martin Bohm</othercollaboratorname>
      <othercollaboratoraddress>Suite 211
Edgecliff Centre
203-233 New South Head Road
Edgecliff
NSW Australia 2027</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Greg Wernicke</othercollaboratorname>
      <othercollaboratoraddress>Suite 211
Edgecliff Centre
203-233 New South Head Road
Edgecliff
NSW Australia 2027</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to determine if injecting corticosteroid into the knee during total knee replacement results in improved pain and function (in the short to medium term).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>6/05/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sam Chia</name>
      <address>PO Box 634
Waverley 
NSW Australia 2024</address>
      <phone>+61283070333</phone>
      <fax />
      <email>skchia@tpg.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sam Chia</name>
      <address>PO Box 634
Waverley 
NSW Australia 2024</address>
      <phone>+61283070333</phone>
      <fax />
      <email>skchia@tpg.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sam Chia</name>
      <address>PO Box 634
Waverley
NSW Australia 2024</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>